Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11798736 | 0.77 | ALDH1A1 (0.34) | GAA | |
| SCHEMBL3137968 | 0.76 | ELANE (0.36) | KMT2A | |
| SCHEMBL114172 | 0.72 | ADRA2A (0.34) | ADRA2AADRA2BADRA2CMEN1KMT2A | |
| SCHEMBL1158351 | 0.72 | ALOX5 (0.42) | MEN1KMT2AGAAPOLB | |
| SCHEMBL28583999 | 0.69 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CMEN1KMT2A | |
| SCHEMBL9510309 | 0.69 | — | — | |
| SCHEMBL27494475 | 0.68 | GAA (0.42) | ADRA2AADRA2BADRA2CKMT2AGAA | |
| SCHEMBL28054801 | 0.67 | LMNA (0.35) | MEN1KMT2APOLB | |
| SCHEMBL27374876 | 0.67 | LMNA (0.35) | ADRA2AADRA2BADRA2CMEN1KMT2A | |
| SCHEMBL28578552 | 0.65 | ALOX15 (0.34) | ADRA2AADRA2BADRA2CMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119140-A1 | CLEAVABLE COMONOMER STRATEGY FOR ACCELERATING REMOVAL OF GEL NAIL POLISH | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4359380-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL) METHYL)BENZYL) AMINO)ISOINDOLINE-1,3-DIONE | Celgene Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024073745-A1 | INHIBITORS OF EGFR OR HER2 AND METHODS OF USE | ARBELLA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201005-A2 | HYDROPHOBIC POLYMER AEROGELS | AEROGEL TECHNOLOGIES, LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023146892-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146896-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023064345-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-4161651-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-2367798-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Cambria Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2337522-A1 | ESOPHAGEAL VALVE | Vysera Biomedical Limited (IE) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011073970-A1 | A GASTROINTESTINAL IMPLANT DEVICE | VYSERA BIOMEDICAL LIMITED (IE) | 2011-06-23 | — | — | WO | disclosed |
| EP-2331525-A2 | HALOFUGINONE ANALOGS FOR INHIBITION OF TRNA SYNTHETASES AND USES THEREOF | President and Fellows of Harvard College (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010057006-A9 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010062372-A2 | METHODS FOR MODULATING NF-KB USING GIBBERELLINS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010059241-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010057006-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010019210-A2 | HALOFUGINONE ANALOGS FOR INHIBITION OF TRNA SYNTHETASES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009153771-A1 | ESOPHAGEAL VALVE | VYSERA BIOMEDICAL LIMITED (IE) | 2009-12-23 | — | — | WO | disclosed |